{"prompt": "['within 28 days before first dose of study treatment.', 'b. Clinically significant hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or', 'other history of significant bleeding (e.g. pulmonary hemorrhage) within 3 weeks prior to the', 'first dose of study drug', 'c.', 'Serious non-healing wound/ulcer/bone fracture', 'd. History of organ allograft (subject has had an allogenic tissue/solid organ transplant)', '10. Biologic response modifiers (e.g. granulocyte colony-stimulating factor) within 4 weeks', 'before study entry. Chronic erythropoietin therapy is permitted provided that no dose', 'adjustments were made within 2 months before first dose of study treatment.', '11. Subjects must have recovered adequately from any toxicity and/or complications from', 'major surgery prior to starting therapy.', '12. Has received a live vaccine within 30 days prior to the first dose of study drug. Examples', 'of live vaccines include, but are not limited to, the following: measles, mumps, rubella,', 'varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG),', 'and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus', 'vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist\u00ae) are live', 'attenuated vaccines and are not allowed.', '13. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in', 'dosing exceeding 10 mg daily of prednisone equivalent) or any other form of', 'immunosuppressive therapy within 7 days prior to the first dose of study drug.', '14. Has active autoimmune disease that has required systemic treatment in the past 2 years', '(i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).', 'Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement', 'therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic', 'treatment.', '15. Has a history of (non-infectious) pneumonitis that required steroids or has current', 'pneumonitis.', '16. Has an active infection requiring systemic therapy.', '17. Has a known history of active Hepatitis B (e.g., hepatitis B surface antigen [HBsAg]) or', 'hepatitis C (e.g., HCV RNA qualitative is detected)', '18. Has uncontrolled HIV defined by a CD4+ count < 350 cells/uL, an AIDS-defining', 'opportunistic infection within the last 12 months prior to study enrollment or documented', 'multidrug resistance that prevents effective HIV therapy', 'Page 14', 'Version Date: 05/08/2020']['19. Has a history or current evidence of any condition, therapy, or laboratory abnormality', \"that might confound the results of the study, interfere with the subject's participation for\", 'the full duration of the study, or is not in the best interest of the subject to participate, in', 'the opinion of the treating investigator.', '5.1.3', 'Lifestyle Restrictions', '5.1.3.1 Meals and Dietary Restrictions', 'Participants should maintain a normal diet unless modifications are required to manage an AE', 'such as diarrhea, nausea or vomiting.', '5.1.3.2 Contraception', 'Lenvatinib and pembrolizumab may have adverse effects on a fetus in utero. Refer to Appendix', '3 for approved methods of contraception for WOCBP and men with WOCBP as sexual partners.', '5.1.4 Pregnancy', 'If a participant inadvertently becomes pregnant while on treatment with pembrolizumab and', 'lenvatinib, the participant will be immediately discontinued from study treatment. The site will', \"contact the participant at least monthly and document the participant's status until the pregnancy\", 'has been completed or terminated. The outcome of the pregnancy will be reported to Merk', 'within 2 working days if the outcome is a serious adverse experience (e.g., death, abortion,', 'congenital anomaly, or other disabling or life-threatening complication to the mother or', 'newborn). The study Investigator will make every effort to obtain permission to follow the', 'outcome of the pregnancy and report the condition of the fetus or newborn to Merkk. If a male', 'participant impregnates his female partner, the study personnel at the site must be informed', 'immediately and the pregnancy must be reported to Merk and followed as described in Section', '7.2.2.', '5.1.5 Use in Nursing Women', 'It is unknown whether lenvatinib or pembrolizumab are excreted in human milk. It is known', 'that lenvatinib and its metabolites are excreted in rat milk. Since many drugs are excreted in', 'human milk, and because of the potential for serious adverse reactions in the nursing infant,', 'participants who are breast-feeding are not eligible for enrollment.', '5.2 Trial Treatments', 'The treatment to be used in this trial is outlined below in Table 2.', 'Table 1. Trial Treatment', 'Drug', 'Dose/Potency', 'Dose', 'Route of', 'Regimen/Treatment', 'Use', 'Frequency', 'Administration', 'Period', 'Pembrolizumab', '200 mg', 'Q3W', 'IV infusion', 'Day 1 of each 3 week', 'Experimental', 'cycle X 4 cycles', 'Page 15', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}